We are pleased to present further results from the EAST-AFNET 4 trial:
Patients with first diagnosed atrial fibrillation are at high risk of cardiovascular events and suitable for early rhythm control: The EAST-AFNET 4 trial
Andreas Goette will present the abstract on the AHA congress in Boston, Sunday, 14. Nov 2021 (EASTERN), 5.49 – 5.57 pm (11.49 pm Europe/Berlin):